Skip to main content Accessibility help
×
Home
  • Print publication year: 2011
  • Online publication date: December 2011

42 - B-cell-based therapies for multiple sclerosis

from Section III - Clinical trials of multiple sclerosis therapies

Summary

In the first of two studies reported by Rose and coworkers, patients with relapsing-remitting multiple sclerosis (RRMS) or secondary-progressive multiple sclerosis (SPMS) were initiated on daclizumab with the same dose. A positive effect on relapses was observed. Safety data coming from daclizumab's regulatory-approved indication in renal transplantation suggest that the drug is overall safe and well tolerated. However, safety data from other of-label indications, such as uveitis, seem to confirm safety concerns regarding a mild increase in infection rate as well as skin reactions. Daclizumab is a novel and promising therapy for MS patients now being tested as monotherapy in a large Phase 3 trial using an active comparator arm. Daclizumab's mechanism of action is not fully understood, but an increase in regulatory immune cells has been related to clinical response and is now thought to play a more important role than direct anti-inflammatory effects derived from IL-2 blockade.

References

1. Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997; 349:589–93.
2. Achiron A, Gabbay U, Gilad R, et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998; 50:398–402.
3. Sorensen PS, Wanscher B, Jensen CV, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing remitting multiple sclerosis. Neurology 1998; 50:1273–81.
4. Weinshenker BG, O’Brien PC, Petterson PM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46:878–86.
5. Hommes OR, Sorensen PS, Fazekas F, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 2004; 364:1149–56.
6. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340:227–8.
7. Alter A, Duddy M, Hebert S, et al. Determinants of human B cell migration across brain endothelial cells. J Immunol 2003; 170:4497–505.
8. Yong VW. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 2002; 59:802–8.
9. Kim HJ, Ifergan I, Antel JP, et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 2004; 172:7144–53.
10. Weber MS, Starck M, Wagenpfeil S, et al. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 2004; 127:1370–8.
11. Weber MS, Prod’homme T, Youssef S, et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 2007; 13:935–43.
12. Begum-Haque S, Christy M, Ochoa-Reparaz J, et al. Augmentation of regulatory B cell activity in experimental allergic encephalomyelitis by glatiramer acetate. J Neuroimmunol 2011; 232:136–44.
13. Kala M, Rhodes SN, Piao WH, et al. B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. Exp Neurol 2010; 221:136–45.
14. Farina C, Weber MS, Meinl E, Wekerle H, Hohlfeld R. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol 2005; 4:567–75.
15. Bar-Or A, Oger J, Gibbs E, et al. Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression? Mult Scler 2009; 15:959–64.
16. Martin F, Chan AC. B cell immunobiology in disease – evolving concepts from the clinic. Annual Rev Immunol 2006; 24:467–496.
17. Duddy, M, Niino M, Adatia F, et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007; 178:6092–9.
18. Stashenko, P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte–specific antigen. J Immunol 1980; 125:1678–85.
19. Cragg MS, Walshe CA, Ivanov A, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. In Curr Dir Autoimmun vol 8:140–174, Karger: Basel, 2005.
20. Maloney DG, Smith B, Appelbaum FR. The anti-tumor effect of monoclonal anti CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines. Blood 1996; 88(Suppl 1):637a.
21. Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101:949–54.
22. Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a Phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003; 21:1746–51.
23. Hainsworth JD, Litchy S, Burris HA III, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:1–67.
24. Edwards JC, Leandro MJ, Cambridge G. B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders. Biochem Soc Trans 2002; 30:824–8.
25. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B-cell depletion. Ann Rheum Dis 2002; 61:883–8.
26. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:2572–81.
27. Leandro MJ, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46:2673–77.
28. Eisenberg R. SLE-rituximab in lupus. Arthritis Res Ther 2003; 5:157–9.
29. D’Arena G, Luigiavigliotti M, Coccaro M, et al. Late and long-lasting response in an adult chronic idiopathic thrombocytopenic purpura after extended course of rituximab. Leuk Lymphoma 2003; 44:561–2.
30. Zaja F, Iacona I, Masolini P, et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 2002; 87:189–95.
31. Pestronk A, Florence J, Miller T, et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003; 74:485–9.
32. Pranzatelli MR, Tate ED, Travestead AL, Verhultst SJ. CSF B cell over-expansion in paraneoplastic opsoclonus-myoclonus syndrome: effect of rituximab, an anti–B-cell monoclonal antibody. Neurology 2003 60(Suppl 1):A395.
33. Cross AH, Stark JL, Lauber J, et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006; 180:63–70.
34. Naismith RT, Piccio L, Lyons JA, et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 2010; 74:1860–7.
35. Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008; 63:395–400.
36. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358:676–88.
37. Hawker K, O’Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66:460–71.
38. Ruhstaller TW, Ambler U, Cerny T. Rituximab: active treatment of central nervous system involvement by non-Hodgkin lymphoma? Ann Oncol 2000; 11:374–5.
39. Bar-Or A, Fawaz L, Fan B, et al. Abnormal B cell cytokine responses: a trigger of T-cell-mediated disease in MS? Ann Neurol 2010; 67:452–61.
40. Genovese MC, Kaine JL, Lowenstein MB, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 2008; 58:2652–61.
41. Kappos L, Calabresi P, O’Connor P, et al. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis: results of a phase II randomized placebo-controlled multicenter trial. Mult Scler 2010; 16:S114.
42. Soelberg Sorensen P, Drulovic J, Havrdova E, et al. Magnetic resonance imaging efficacy of ofatumumab in relapsing-remitting multiple sclerosis – 24-week results of a phase II study. Mult Scler 2010; 16:S136.
43. Cambridge G, Leandro MJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003; 48:2146–54.
44. Piccio L, Naismith RT, Trinkaus K, et al. Changes in B and T lymphocytes and chemokines with rituximab treatment in multiple sclerosis. Arch Neurol 2010; 67:707–14.
45. Monson N, Cravens P, Frohman E, et al. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 2005; 62:258–64.
46. Petereit HF, Moeller-Hartmann W, Reske D, Rubbert A. Rituximab in a patient with multiple sclerosis–effect on B cells, plasma cells and intrathecal IgG synthesis. Acta Neurol Scand 2008; 117:399–403.
47. Stuve O, Cepok S, Elias B, et al. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol 2005; 62:1620–3.
48. Gausas J, Paterson PY, Day ED, Dal Canto MS. Intact B-cell activity is essential for complete expression of experimental allergic encephalomyelitis in Lewis rats. Cell Immunol 1982; 72:360–6.
49. Willenborg DO, Sjollema P, Danta G. Immunoglobulin deficient rats as donors and recipients of effector cells of allergic encephalomyelitis. J Neuroimmunol 1986; 11:93–103.
50. Lyons JA, San M, Happ MP, Cross AH. B-cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. Eur J Immunol 1999; 29:3432–9.
51. Genain CP, Nguyen MH, Letvin NL, et al. Antibody facilitation of multiple sclerosis-like lesions in nonhuman primate. J Clin Invest 1995; 96:2966–74.
52. Schluesener HJ, Sobel RA, Linington C, Weiner HL. A monoclonal antibody against myelin oligodendroctye glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol 1987; 139:4016–20.
53. Robinson WH, Fontoura P, Lee BJ, et al. Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol 2003; 21:1033–9.
54. Esiri MM. Immunoglobulin-containing cells in multiple sclerosis plaques. Lancet 1977;ii:478–80.
55. Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999; 5:170–5.
56. Lyons JA, Ramsbottom MJ, Cross AH. Critical role of antigen-specific antibody in EAE induced by recombinant MOG. Eur J Immunol 2002; 32:1905–13.
57. Antel JP, Bar-Or A. Do myelin antibodies predict the diagnosis of multiple sclerosis? N Engl J Med 2003; 349:107–9.
58. Lou YH, Park KK, Agersborg S, et al. Retargeting T Cell-mediated inflammation: a new perspective on autoantibody action. J Immunol 2000; 164:5251–7.
59. Rodriguez M, Miller D, Lennon V. Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology 1996; 46:538–45.
60. Reindl M, Khantane S, Ehling R, et al. Serum and cerebrospinal fluid antibodies to Nogo-A in patients with multiple sclerosis and acute neurological disorders. J Neuroimmunol 2003; 145:139–47.
61. Fontoura P, Ho PP, DeVoss J, et al. Immunity to the extracellular domain of Nogo-A modulates experimental autoimmune encephalomyelitis. J Immunol 2004; 173:6981–92.
62. Siden A. Isoelectric focusing and crossed immunoelectrofocusing of CSF immunoglobulins in MS. J Neurol 1979; 221:39–51.
63. Andersson M, Yu M, Soderstrom M, et al. Multiple MAG peptides are recognized by circulating T and B lymphocytes in polyneuropathy and multiple sclerosis. Eur J Neurol 2002; 9:243–51.
64. O’Connor KC, Bar-Or A, Hafler DA. The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. J Clin Immunol 2001; 21:81–92.
65. Qin Y, Duquette P, Zhang Y, et al. Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Invest 1998; 102:1045–50.
66. Owens GP, Kraus H, Burgoon MP, et al. Restricted use of VH4 germline segments in an acute multiple sclerosis brain. Ann Neurol 1998; 43:236–43.
67. Baranzini SE, Jeong MC, Butunoi C, et al. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol 1999; 163:5133–44.
68. Colombo M, Dono M, Gazzola P, et al. Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J Immunol 2000; 164:2782–9.
69. Cepok S, Rosche B, Grummel V et al. Short lived plasma blasts are the main B cell effector subset during the course of MS. Brain 2005; 128:1667–76.
70. Walsh MJ, Tourtelotte WW. Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA and IgM in multiple sclerosis. J Exp Med 1986; 163:41–53.
71. Hemmer B, Cepok S, Nessler S, Sommer N. Pathogenesis of multiple sclerosis: an update on immunology. Curr Opin Neurol 2002; 15:227–31.
72. Rudick MA, Medendorp SV, Namey M, et al. Multiple sclerosis progression in a natural history study: predictive value of cerebrospinal fluid free kappa light chains. Mult Scler 1995; 1:150–5.
73. Zeman D, Adam P, Kalistova H, et al. Cerebrospinal fluid cytologic findings in multiple sclerosis. A comparison between patient subgroups. Acta Cytol 2001; 45:51–9.
74. Izquierdo G, Angulo S, Garcia-Moreno JM, et al. Intrathecal IgG synthesis: marker of progression in multiple sclerosis patients. Acta Neurol Scand 2002; 105:158–63.
75. Villar LM, Masjuan J, Gonzalez-Porque P, et al. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann Neurol 2003; 53:222–6.
76. Trotter JL, Rust RL. Human cerebrospinal Fluid immunology. In: Brumbach R, Herndon R, eds. Cerebrospinal Fluid, Martinus Nyhoff: Amsterdam, 1989:179–226.
77. Cross AH, Trotter JL, Lyons JA. B cells and antibodies in CNS demyelinating disease. J Neuroimmunol 2001; 122:1–14.
78. Lucchinetti CF, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47:707–17.
79. Storch MK, Piddlesden S, Haltia M, et al. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol 1998; 43:465–71.
80. Gay FW, Drye TJ, Dick GW, Esiri MM. The application of multifactorial cluster analysis in the staging of plaques in early MS. Identification and characterization of the primary demyelinating lesions. Brain 1997; 120:1461–83.
81. O’Connor KC, Appel H, Bregoli L, et al. Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J Immunol 2005; 175:1974–82.
82. Cruz M, Olsson T, Ernerudh J, et al. Immunoblot detection of oligoclonal anti-myelin basic protein IgG antibodies in cerebrospinal fluid in multiple sclerosis. Neurology 1987; 37:1515–19.
83. Olsson T, Baig S, Hojeberg B, Link H. Antimyelin basic protein and antimyelin antibody-producing cells in multiple sclerosis. Ann Neurol 1990; 27:132–6.
84. Reindl M, Linington C, Brehm U, et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain 1999; 122:2047–56.
85. Egg R, Reindl M, Deisenhammer F, et al. Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis. Mult Scler 2001; 7:285–9.
86. Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003; 349:139–45.
87. Lim ET, Berger T, Reindl M, et al. Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler 2005; 11:492–4.
88. O’Connor KC, Lopez-Amaya C, Gagne D, et al. Anti-myelin antibodies modulate clinical expression of childhood multiple sclerosis. J Neuroimmunol. 2010; 223:92–9.
89. Sadatipour BT, Greer JM, Pender MP. Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol 1998; 44:980–3.
90. Mata S, Lolli F, Soderstrom M, et al. Multiple sclerosis is associated with enhanced B cell responses to the ganglioside GD1a. Mult Scler 1999; 5:379–88.
91. Menge T, Lalive PH, von Budingen HC, et al. Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. J Allergy Clin Immunol 2005; 116:453–9.
92. O’Connor KC, Chitnis T, Griffin DE, et al. Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. J Neuroimmunol 2003; 136:140–8.
93. Lily O, Palace J, Vincent A. Serum autoantibodies to cell surface determinants in multiple sclerosis: a flow cytometric study. Brain 2004; 127:269–79.
94. Menge T, Lalive PH, von Budingen HC, et al. Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. J Allergy Clin Immunol 2005; 116:453–9.
95. Zhou D, Srivastava R, Nessler S, et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci USA 2006; 103:19057–62.
96. Lalive PH, Menge T, Delarasse C, et al. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci USA 2006; 103:2280–5.
97. O’Connor KC, McLaughlin KA, De Jager PL, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 2007; 13:211–17.
98. McLaughlin KA, Chitnis T, Newcombe J, et al. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol 2009; 183:4067–76.
99. Brilot F, Dale RC, Selter RC, et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 2009; 66:833–42.
100. Chan A, Decard BF, Franke C, et al. Serum antibodies to conformational and linear epitopes of myelin oligodendrocyte glycoprotein are not elevated in the preclinical phase of multiple sclerosis. Mult Scler 2010; 16:1189–92.
101. Shlomchik MJ, Madaio MP, Ni D, et al. The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med 1994; 180:1295–306.
102. Chan O T, Hannum LG, Haberman AM, et al. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999; 189:1639–48.
103. Falcone M, Lee J, Patstone G, et al. B lymphocytes are crucial antigen-presenting cells in the pathogenic autoimmune response to GAD65 antigen in nonobese diabetic mice. J Immunol 1998; 161:1163–8.
104. Constant SL. B lymphocytes as antigen-presenting cells for CD4+ T cell priming in vivo. J Immunol 1999; 162:5695–703.
105. Genc K, Dona DL, Reder AT. Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J Clin Invest 1997; 99:2664–71.
106. Bar-Or A, Oliveira EML, Anderson DE, et al. Immunological memory: contribution of memory B cells expressing costimulatory molecules in the resting state. J Immunol 2001; 167:5669–77.
107. Lanzavecchia A. Receptor-mediated antigen uptake and its effect on antigen presentation to class II restricted T lymphocytes. Annu Rev Immunol 1990; 8:773–93.
108. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995; 80:695–705.
109. Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008; 118:3420–30.
110. Weber MS, Prod'homme T, Patarroyo JC, et al. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol 2010; 68:369–83.
111. Corcione A, Casazza S, Ferretti E, et al. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci USA 2004; 101:11064–9.
112. Uccelli A, Aloisi F, Pistoia V. Unveiling the enigma of the CNS as a B-cell fostering environment. Trends Immunol 2005; 26:254–9.
113. Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130:1089–104.
114. Lund FE, Garvy BA, Randall TD, Harris DP. Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr Dir Autoimmun 2005; 8:25–54.
115. Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell effector cytokines: A role in immune regulation? J Immunol 2004; 172:3422–7.
116. Wolf SD, Dittel BN, Hardardottir F, Janeway CA, Jr. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med 1996; 184:2271–8.
117. Fillatreau S, Sweenie CH, McGeachy MJ, et al. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002; 3:944–50.
118. Correale J, Farez M, Razzitte G. Helminth infections associated with multiple sclerosis induce regulatory B cells. Ann Neurol 2008; 64:187–99.
119. Serafini B, Rosicarelli B, Magliozzi R, et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004; 14:164–74.
120. Barone F, Bombardieri M, Manzo A, et al. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjogren's syndrome. Arthritis Rheum 2005; 52:1773–84.
121. Weyand CM, Kurtin PJ, Goronzy JJ. Ectopic lymphoid organogenesis: a fast track for autoimmunity. Am J Pathol 2001; 159:787–93.
122. Alter A, Duddy M, Hebert S, et al. Determinants of human B cell migration across brain endothelial cells. J Immunol 2003; 170:4497–505.
123. Bar-Or A, Nuttall RK, Duddy M, et al. Analyses of all matrix metalloproteinase members in leuckocytes: monocytes as major inflammatory mediators in multiple sclerosis. Brain 2003; 126:2738–49.
124. Ascherio A, Munger KL, Lennette ET, et al. Epstein–Barr virus antibodies and risk of multiple sclerosis: a prospective study. J Am Med Assoc 2001; 286:3083–8.
125. Lang HL, Jacobsen H, Ikemizu S, et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002; 3:940–3.
126. Alotaibi S, Kennedy J, Tellier R, Stephens D, Banwell B. Epstein-Barr virus in pediatric multiple sclerosis. J Am Med Assoc 2004; 291:1875–9.
127. Pender MP. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol 2003; 24:584–8.
128. Banwell B, Krupp L, Tellier R, et al. Clinical features and viral serologies in children with multiple sclerosis: results of a multinational cohort study. Lancet Neurology 2007; 6:773–81.
129. Ascherio A, Bar-Or A. EBV and brain matter(s)? Neurology 2010; 74:1092–5.